ATE363483T1 - Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen - Google Patents

Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen

Info

Publication number
ATE363483T1
ATE363483T1 AT04779540T AT04779540T ATE363483T1 AT E363483 T1 ATE363483 T1 AT E363483T1 AT 04779540 T AT04779540 T AT 04779540T AT 04779540 T AT04779540 T AT 04779540T AT E363483 T1 ATE363483 T1 AT E363483T1
Authority
AT
Austria
Prior art keywords
disorder
metabolite
inhibitor
symptom
disease
Prior art date
Application number
AT04779540T
Other languages
English (en)
Inventor
Anima Ghosal
Wei Tong
Swapan Chowdhury
Shmuel Zbaida
Mark Wirth
Kevin Alton
James Patrick
Craig Boyle
Andrew Stamford
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE363483T1 publication Critical patent/ATE363483T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04779540T 2003-07-31 2004-07-29 Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen ATE363483T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49221803P 2003-07-31 2003-07-31

Publications (1)

Publication Number Publication Date
ATE363483T1 true ATE363483T1 (de) 2007-06-15

Family

ID=34115611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04779540T ATE363483T1 (de) 2003-07-31 2004-07-29 Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen

Country Status (11)

Country Link
US (1) US7312223B2 (de)
EP (1) EP1648895B1 (de)
JP (1) JP2007500714A (de)
CN (1) CN1860119A (de)
AT (1) ATE363483T1 (de)
CA (1) CA2533715A1 (de)
DE (1) DE602004006756T2 (de)
ES (1) ES2284056T3 (de)
HK (1) HK1082739A1 (de)
MX (1) MXPA06001195A (de)
WO (1) WO2005012303A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60307628T2 (de) * 2002-05-31 2007-08-09 Schering Corporation Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
KR20090087795A (ko) * 2008-02-13 2009-08-18 한양대학교 산학협력단 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
US20100261737A1 (en) * 2009-04-10 2010-10-14 Medtronic Vascular, Inc. Method of Treating Erectile Dysfunction
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2013054153A1 (en) 2011-10-11 2013-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Nutlin compounds for use in he treatment of pulmonary hypertension
CN106770618A (zh) * 2015-11-20 2017-05-31 中国康复研究中心 一种建立急性缺血性脑卒中特征蛋白的质谱模型的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
CA2098846A1 (en) * 1990-12-21 1992-06-22 David G. Smith Xanthine derivatives
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
WO1994019351A1 (en) * 1993-02-26 1994-09-01 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60307628T2 (de) 2002-05-31 2007-08-09 Schering Corporation Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen
TW200404802A (en) 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs

Also Published As

Publication number Publication date
HK1082739A1 (en) 2006-06-16
EP1648895A1 (de) 2006-04-26
MXPA06001195A (es) 2006-04-11
ES2284056T3 (es) 2007-11-01
US7312223B2 (en) 2007-12-25
DE602004006756T2 (de) 2008-01-24
JP2007500714A (ja) 2007-01-18
CN1860119A (zh) 2006-11-08
WO2005012303A1 (en) 2005-02-10
CA2533715A1 (en) 2005-02-10
US20050026939A1 (en) 2005-02-03
DE602004006756D1 (de) 2007-07-12
EP1648895B1 (de) 2007-05-30

Similar Documents

Publication Publication Date Title
HK1082739A1 (en) Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment oferectile dysfunction
ATE554765T1 (de) Imidazoä1,2-aüpyridine und ihre verwendung als arzneimittel
Trinity et al. Passive leg movement and nitric oxide-mediated vascular function: the impact of age
WO2005123718A3 (en) Benzimidazolone carboxylic acid derivatives
BRPI0513444A (pt) antagonistas do receptor da histamina 3
JP2013056911A (ja) 運動障害の予防および／または治療剤
JP2007537293A5 (de)
CN108697807A (zh) 代谢功能障碍引起的肿瘤的治疗
DE60238929D1 (de) Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind
CN100999517A (zh) 吡唑甲酰胺衍生物,药物组合物和其制备方法
NZ597222A (en) Substituted 8-[6-Amino-3-Pyridyl]Xanthines
JP7137650B2 (ja) テトラヒドロイソキノリン誘導体
JP2007500714A5 (de)
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
JPH0273015A (ja) 置換３，４‐ジヒドロ‐２ｈ‐ベンゾピラン類の肺の閉鎖性機能障害および／または輸出尿路の障害の治療薬としての使用
EP2094285B1 (de) Spezialextrakt und seine verwendung zur hemmung des abbaus von cyclischem guanosinmonophosphat (cgmp)
Akbarinia et al. Effects of different types of isokinetic contraction on hemodynamic parameters in men.
ATE496621T1 (de) Imidazoä2,1-büthiazole und ihre verwendung als pharmazeutika
CN107998140B (zh) 化合物r1的用途
Boss 20 Years of Medicinal Chemistry–Always Look at the Bright Side (of Life)
RU2010148433A (ru) Производные бензоциклогептана и бензоксепина
CN106986878A (zh) 一种预防和治疗荨麻疹的药物及其制备方法
Mishra et al. Auditory, visual and postural reaction time among middle aged type 2 diabetics and healthy individuals–a cross-sectional study
Khabibulina et al. Impact of metabolic therapy on the state of cerebral hemodynamics in hypoestrogenemia
Bofosa et al. Impact of a program of adapted physical activity on the morphological, physiological, and biological parameters of sedentary hypertensive postmenopausal women

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties